The future leaves
signals in time.

In this first-person account, the author describes a mother-daughter quest to find others in an ultra-rare genetic community. A pediatric geneticist had warned her not to google the condition, and it took her five years to disobey. The supplied context offers limited further detail.

A large analysis of 22 studies found that trans fats naturally present in dairy foods such as milk, butter, yogurt, and cheese do not appear to raise the risk of heart disease or type 2 diabetes. Unlike industrial trans fats from partially hydrogenated oils, dairy trans fats showed no meaningful harmful effects on blood fats in controlled trials and were not linked to higher rates of heart disease, stroke, cardiovascular death, or diabetes in long-term studies.

A Stanford-designed molecule turns a major lymphoma-promoting protein against cancer cells, activating their own self-destruct machinery instead of simply blocking tumor growth. In mice, the treatment completely eliminated aggressive human lymphoma tumors within 11 days, although much more testing is needed before it could reach patients.

Researchers report that eating more sugar while taking antibiotics was linked to greater disruption of the gut microbiome and increased growth of potentially harmful bacteria. They suggest temporarily cutting back on sweets during and after antibiotic treatment could be a simple way to reduce this damage, though clinical trials are still needed.

Scientists at UC San Francisco have developed a way to create cancer-fighting CAR-T cells directly inside the body, using a two-particle delivery system to send CRISPR gene-editing tools and new cancer-targeting DNA specifically into T cells, where the DNA was inserted at a precise genomic location. The approach could potentially avoid the slow, extremely expensive process of removing, engineering, and reinfusing a patient's immune cells.

According to STAT, a promising therapy for Duchenne muscular dystrophy is currently available to only a fortunate few patients. The article notes that exon-skipping drugs present a critical test for the FDA's goal of encouraging treatments for rare diseases.

Caribou Biosciences, a biotech co-founded by Jennifer Doudna, is shutting down after failing to raise the money necessary to fund a late-stage clinical trial of its off-the-shelf CAR-T therapy for lymphoma.

Scientists found that disrupting the chemical messages bacteria use to communicate can push dental plaque toward a healthier microbial balance. The approach could lead to gum disease treatments that control harmful bacteria without destroying beneficial species.

According to Nature, genome accessibility can reveal disease risk that gene expression analysis misses. No further details, methods, or study scope are provided in the available context.

Researchers found that most colorectal cancer patients aged 21 or younger already had Stage III or IV disease when diagnosed. Because symptoms such as rectal bleeding, weight loss, abdominal pain, and bowel changes may be overlooked, the researchers are calling for greater vigilance.

Stanford scientists found that blocking a protein that becomes more abundant with age can regrow damaged knee cartilage. In old mice, the treatment restored naturally lost cartilage and helped prevent osteoarthritis after ACL-like knee injuries, and human cartilage from knee replacement patients began producing new, functional joint cartilage after exposure to the same inhibitor. Evidence so far comes from mouse models and ex vivo human tissue.

In an opinion piece, H. Gilbert Welch argues that the FDA should not approve Grail's multicancer screening test, which he describes as ineffective, writing that “telling more people they have cancer is not progress; progress is having fewer people die from cancer.” This is the author's opinion, not a regulatory decision.

MIT researchers found that a ketogenic diet increased small-intestinal tumors in cancer-prone mice while reducing colon tumors. They traced the higher risk not to ketones but to intestinal stem cells burning the diet's high fat, which sped cell multiplication; the finding comes from mouse models, not human evidence.

Nature Medicine describes MAGIC, an international network for evaluating generative artificial intelligence in global health. The feed provides no further details on its members, methods, or current status.

A report covers extended follow-up of an in vivo BCMA CAR-T therapy for relapsed/refractory multiple myeloma. No further context was provided beyond the headline, so the specific findings and conclusions of this follow-up cannot be confirmed from the available information.

Genetic analysis of hundreds of tiny bone fragments from Denisova cave, the site that yielded the first fossil remains of the Denisovans, has revealed that the region was once also home to a previously unknown, extinct species of yak, New Scientist reports.

According to STAT+, Eli Lilly's Jaypirca has won FDA approval as a first-line therapy for previously untreated chronic lymphocytic leukemia and small lymphocytic lymphoma.